Research Paper Volume 15, Issue 22 pp 12907—12926
The necroptosis signature and molecular mechanism of lung squamous cell carcinoma
Figure 7. Heatmaps showing of the distribution of clinical features between the two risk groups in (A) TCGA_LUSC and (B) GSE73403 datasets. (C) Survival of bladder cancer patients grouped on the basis of necroptosis signature (IMvigor210). (D) Treatment response of the high-risk and low-risk groups (***p < 0.0001). (E) ROC curve showing predictive capacity of the necroptosis signature for treatment response; (F) Difference analysis of treatment response of the high-risk and low-risk groups in GSE91061 (****p < 0.0001). (G) ROC curve showing predictive capacity of the necroptosis signature for treatment response. (H) Survival of renal clear cell carcinoma patients grouped on the basis of necroptosis signature. (I) Treatment response of the high-risk and low-risk groups (**p < 0.01). (J) ROC curve showing predictive capacity of the necroptosis signature for treatment response.